Skip to main content

Medigene Value Stock - Dividend - Research Selection

Medigene

ISIN: DE000A1X3W00 , WKN: A1X3W0

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and a research collaboration with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Martinsried, Germany.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS